|

Ceralasertib Clinical Trials

7 actively recruiting trials across 3 locations

No change since May 2026

Also known as: ATR Kinase Inhibitor AZD6738, AZD-6738, AZD6738

Pipeline

Phase 1: 1Phase 2: 5Phase 1/2: 1

Top Sponsors

  • University of Leeds1
  • SWOG Cancer Research Network1
  • Muhammad Furqan1
  • Mario Negri Institute for Pharmacological Research1
  • M.D. Anderson Cancer Center1

Indications

Other4 trials

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Phase 1
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Phase 2
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Phase 2

Loma Linda, California1 trial

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Loma Linda University Medical Center

Phase 2

Chicago, Illinois1 trial

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

University of Illinois Medical Center

Phase 2

Houston, Texas1 trial

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.